Immatics and BMS ink deal worth up to $920 million

14 December 2021
immatics-logo-big

Germany-based Immatics (Nasdaq: IMTX), a company focused on the discovery and development of T cell-redirecting cancer immunotherapies, has entered into a license, development and commercialization agreement with US pharma major Bristol Myers Squibb (NYSE: BMY).

The agreement secures BMS a global exclusive license to Immatics’ TCR bispecific program, IMA401.

Following the announcement of the news, Immatics’ share price rose 5% in the first two hours of trading on Tuesday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology